SRR33532785
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.380
- PANCREAS_BETA_CELLS+0.270
- PROTEIN_SECRETION+0.270
- E2F_TARGETS+0.250
- OXIDATIVE_PHOSPHORYLATION+0.250
- APICAL_SURFACE+0.240
- KRAS_SIGNALING_UP+0.220
- ALLOGRAFT_REJECTION+0.210
- ANDROGEN_RESPONSE+0.190
- MTORC1_SIGNALING+0.190
Top 10 suppressed
- NOTCH_SIGNALING-0.390
- WNT_BETA_CATENIN_SIGNALING-0.330
- HEDGEHOG_SIGNALING-0.260
- P53_PATHWAY-0.160
- PEROXISOME-0.160
- ANGIOGENESIS-0.150
- ESTROGEN_RESPONSE_EARLY-0.130
- HYPOXIA-0.130
- MYC_TARGETS_V2-0.120
- MYOGENESIS-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | AUR-AERW-TTM1-A-1-1-R-A742-41 | — | C | 0.758 |
| 2 | SRR8518384 | — | D | 0.718 |
| 3 | SRR27320672 | — | — | 0.717 |
| 4 | SRR1797278 | — | cohortSC | 0.712 |
| 5 | MNG637 | — | — | 0.709 |
| 6 | 20020064.LumB | — | B | 0.705 |
| 7 | TCGA-46-3769-01A-01R-0980-07 | — | cohortA1 | 0.702 |
| 8 | SRR12696791 | — | — | 0.686 |
| 9 | ULC0548T_S67 | — | cohortSQ1 | 0.675 |
| 10 | 66b4502b-d393-4664-a317-430ec1ad4b3b | — | — | 0.666 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.380 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.270 | Cobimetinib | — uncovered |
| PROTEIN_SECRETION | 0.270 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.250 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.250 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.240 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.220 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.210 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.190 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.190 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.180 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.160 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.160 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.160 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.120 | Remibrutinib | — uncovered |
| COAGULATION | 0.100 | Binimetinib | — uncovered |
| COMPLEMENT | 0.100 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.090 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.090 | Idelalisib | — uncovered |
| APOPTOSIS | 0.080 | Idelalisib | — uncovered |